Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ASND

Ascendis Pharma A/S ADR

May 17 • 10:32AM ET

121.93

Dollar change -0.87
Percentage change -0.71	%

Healthcare • Biotechnology • Denmark • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.26	Insider Own	1.33%	Shs Outstand	56.61M	Perf Week	-8.64%
Market Cap	6.90B	Forward P/E	-	EPS next Y	-0.44	Insider Trans	0.00%	Shs Float	55.86M	Perf Month	-13.46%
Income	-521.07M	PEG	-	EPS next Q	-1.44	Inst Own	107.14%	Short Float	6.62%	Perf Quarter	-22.03%
Sales	287.96M	P/S	23.97	EPS this Y	43.83%	Inst Trans	3.65%	Short Ratio	10.74	Perf Half Y	31.15%
Book/sh	-2.84	P/B	-	EPS next Y	91.58%	ROA	-50.22%	Short Interest	3.70M	Perf Year	34.58%
Cash/sh	7.79	P/C	15.64	EPS next 5Y	-	ROE	-867.62%	52W Range	83.75 - 161.00	Perf YTD	-3.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.87%	ROI	-99.69%	52W High	-24.27%	Beta	0.57
Dividend TTM	-	Quick Ratio	2.50	Sales past 5Y	182.00%	Gross Margin	76.23%	52W Low	45.59%	ATR (14)	5.19
Dividend Ex-Date	-	Current Ratio	3.56	EPS Y/Y TTM	14.73%	Oper. Margin	-171.22%	RSI (14)	25.88	Volatility	5.09% 3.90%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	443.69%	Profit Margin	-180.95%	Recom	1.43	Target Price	179.84
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	56.33%	Payout	-	Rel Volume	1.41	Prev Close	122.80
Sales Surprise	21.28%	EPS Surprise	-56.56%	Sales Q/Q	534.07%	Earnings	May 02 AMC	Avg Volume	344.18K	Price	121.93
SMA20	-10.19%	SMA50	-14.76%	SMA200	2.43%	Trades		Volume	97,851	Change	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-23	Initiated	Jefferies	Buy	$150
Jun-14-23	Resumed	Credit Suisse	Neutral	$89
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$151 → $108
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy	$174
Aug-30-22	Resumed	Berenberg	Buy	$166
Mar-28-22	Resumed	Wedbush	Outperform	$163
Mar-15-22	Upgrade	BofA Securities	Neutral → Buy	$148 → $161
Mar-01-22	Initiated	Citigroup	Buy	$187
Feb-14-22	Upgrade	Oppenheimer	Perform → Outperform	$170
Jan-06-22	Initiated	Cowen	Market Perform	$136
Dec-08-21	Initiated	Wells Fargo	Overweight	$176
Oct-20-21	Downgrade	BofA Securities	Buy → Neutral	$164 → $169
Mar-30-21	Downgrade	Oppenheimer	Outperform → Perform
Mar-11-21	Resumed	Stifel	Buy	$190
Dec-17-20	Initiated	Berenberg	Buy	$216
Sep-14-20	Resumed	JP Morgan	Overweight	$160
Mar-20-20	Initiated	Oppenheimer	Outperform	$199
Oct-11-19	Initiated	Morgan Stanley	Overweight	$128

Show Previous Ratings

May-15-24 01:57PM	FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months (Benzinga)
10:44AM	FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing (Zacks)
May-14-24 04:07PM	US Equity Markets Close Higher Tuesday as Producer Prices Rise (MT Newswires) -5.45%
03:20PM	Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop (MT Newswires)
02:47PM	UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy (Reuters)
02:38PM	Loading…
02:38PM	FDA extends review of Ascendis Pharma's hormone disorder therapy (Reuters)
02:31PM	Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism (GlobeNewswire)
May-13-24 09:29AM	Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH (MT Newswires)
08:30AM	Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial (GlobeNewswire)
May-09-24 08:30AM	Latest Clinical and Quality-of-Life Data for TransCon PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 (GlobeNewswire)
May-06-24 09:59AM	Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:49AM	Ascendis Pharma Q1 Net Loss Widens, Revenue Rises (MT Newswires)
May-02-24 09:57PM	ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024 (InvestorPlace)
04:01PM	Ascendis Pharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 04:46PM	Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 (GlobeNewswire)
11:33AM	Loading…
Apr-24-24 11:33AM	Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism (MT Newswires)
08:34AM	Why Earnings Season Could Be Great for Ascendis Pharma (ASND) (Zacks)
08:30AM	United Kingdom's MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Apr-02-24 06:13AM	Biotech With 520% Sales Growth Nears Next Buy Point (Investor's Business Daily)
Mar-22-24 12:09PM	Two Health Care Stocks Outperform S&P 500, Offer Entries (Investor's Business Daily)
05:27AM	Ascendis Pharma A/S (ASND) Rose on Positive Trial Results (Insider Monkey)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-07-24 08:14AM	Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4 (Insider Monkey)
Mar-04-24 08:30AM	Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-15-24 12:00PM	Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy? (Zacks)
09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Feb-08-24 10:07AM	Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-07-24 04:01PM	Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
08:30AM	Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-24 08:46AM	Why Earnings Season Could Be Great for Ascendis Pharma (ASND) (Zacks)
04:15PM	Loading…
Jan-31-24 04:15PM	Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 (GlobeNewswire)
04:01PM	Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Jan-29-24 08:30AM	New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors (GlobeNewswire)
Jan-08-24 06:01PM	Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey (GlobeNewswire) +6.57%
08:20AM	Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries (GlobeNewswire)
Jan-07-24 05:45PM	Ascendis Pharma Introduces Vision 2030 (GlobeNewswire)
02:00PM	Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries (PR Newswire)
Dec-28-23 04:15PM	Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 08:30AM	Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon CNP (Navepegritide) at 100 g/kg/week (GlobeNewswire)
Dec-19-23 08:30AM	TransCon hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency (GlobeNewswire)
Dec-11-23 08:30AM	FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism (GlobeNewswire)
Nov-29-23 04:30AM	Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan (GlobeNewswire) +7.12%
Nov-20-23 08:00AM	Ascendis Pharma Announces European Commission Approval of YORVIPATH (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Nov-15-23 08:00AM	Ascendis Pharma Resubmits NDA for TransCon PTH to the U.S. FDA (GlobeNewswire)
Nov-08-23 02:07PM	Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:01PM	Ascendis Pharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 09:55AM	Does Ascendis Pharma A/S (ASND) Have the Potential to Rally 51.72% as Wall Street Analysts Expect? (Zacks)
Oct-31-23 08:30AM	Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission (GlobeNewswire)
Oct-26-23 09:35AM	Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:30AM	Ascendis Presents Updated and New TransCon IL-2 Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023 (GlobeNewswire)
Oct-16-23 04:01PM	Ascendis Pharma Presents TransCon PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023 (GlobeNewswire)
Oct-02-23 08:00AM	Ascendis Presents TransCon PTH Data at the American Thyroid Association Annual Meeting (GlobeNewswire)
Sep-23-23 07:00AM	Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency (GlobeNewswire)
Sep-22-23 09:24AM	Heres What Caused the Volatility in Ascendis Pharma A/S (ASND) (Insider Monkey)
Sep-15-23 08:00AM	Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency (GlobeNewswire)
07:27AM	Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock? (Zacks)
Sep-14-23 12:22PM	Ascendis Pharma Receives Positive CHMP Opinion for TransCon PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Sep-06-23 12:11PM	Ascendis Pharma A/S (ASND): A Deep Dive into Its Performance Potential (GuruFocus.com)
11:41AM	Is Ascendis Pharma A/S (ASND) Too Good to Be True? A Comprehensive Analysis of a Potential ... (GuruFocus.com)
08:21AM	Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript (Insider Monkey)
Sep-05-23 04:15PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
04:03PM	Ascendis Pharma Reports Second Quarter 2023 Financial Results (GlobeNewswire)
04:01PM	New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism (GlobeNewswire)
04:01PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
Aug-28-23 09:55AM	Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know (Zacks)
Aug-24-23 08:30AM	Ascendis Pharma A/S Announces Three Upcoming Investor Presentations (GlobeNewswire)
07:09AM	Heres Why Ascendis Pharma A/S (ASND) Declined in Q2 (Insider Monkey)
Aug-23-23 04:48PM	Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders (PR Newswire)
Aug-15-23 08:30AM	Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023 (GlobeNewswire)
Aug-10-23 09:55AM	How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35% (Zacks)
Aug-08-23 06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Jul-25-23 12:19AM	Heres Why Baron Health Care Fund Harvested Ascendis Pharma A/S (ASND) (Insider Monkey)
Jul-23-23 08:45AM	Shareholders have faith in loss-making Ascendis Pharma (NASDAQ:ASND) as stock climbs 3.1% in past week, taking five-year gain to 36% (Simply Wall St.)
Jun-29-23 08:10AM	Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug (Zacks)
Jun-17-23 05:30PM	One-Year Data from Phase 3 Trial of TransCon PTH in Adults with Hypoparathyroidism Presented at ENDO 2023 (GlobeNewswire)
Jun-13-23 07:00AM	Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023 (GlobeNewswire)
Jun-07-23 08:30AM	Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-05-23 05:30PM	Ascendis Pharma Opens Compassionate Use Program for TransCon PTH (palopegteriparatide) in Germany (GlobeNewswire)
May-31-23 08:30AM	Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates (GlobeNewswire)
May-25-23 08:30AM	Ascendis Pharma to Host Oncology Program Update on May 31 (GlobeNewswire)
May-13-23 07:00PM	Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023 (GlobeNewswire)
May-03-23 04:15PM	Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference (GlobeNewswire) +6.48%
06:08AM	Need To Know: Analysts Are Much More Bullish On Ascendis Pharma A/S (NASDAQ:ASND) Revenues (Simply Wall St.)
May-01-23 03:02PM	FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism (Benzinga) +23.99%
11:45AM	Why Shares of Ascendis Pharma Are Climbing Monday (Motley Fool)
07:09AM	U.S. FDA declines to approve Ascendis' hormone disease therapy (Reuters)
07:00AM	U.S. Food & Drug Administration Issues Complete Response Letter for TransCon PTH in Hypoparathyroidism (GlobeNewswire)
Apr-27-23 04:01PM	Ascendis Pharma Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-22-23 08:11AM	An Intrinsic Calculation For Ascendis Pharma A/S (NASDAQ:ASND) Suggests It's 20% Undervalued (Simply Wall St.)
Apr-13-23 08:30AM	Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27 (GlobeNewswire)
Apr-12-23 09:18AM	Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Apr-06-23 04:22PM	Why Ascendis Pharma Stock Is Crashing This Week (Motley Fool)
Apr-04-23 12:43PM	Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies (Zacks)
Apr-03-23 04:07PM	Ascendis Stock Plunges As FDA Identifies Deficiencies In Company's New Drug Application (Investor's Business Daily) -32.07%
01:10PM	Ascendis Pharma Flags Regulatory Delay In US For Its Hypoparathyroidism Candidate (Benzinga)
12:28PM	Why Ascendis Pharma Stock Is Plunging Today (Motley Fool)
07:05AM	Ascendis Pharmas Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon IL-2 / Accepted for Online Publication at ASCO 2023 (GlobeNewswire)
07:00AM	Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH in Hypoparathyroidism (GlobeNewswire)
Mar-17-23 03:35AM	Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last? (Zacks)
Mar-10-23 08:00AM	Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASND

Ascendis Pharma A/S ADR

Upgrade your FINVIZ experience